| 廖艳林,朱浩,朱根源,陈慧敏,刘鹏,明冠.营心宁胶囊联合辛伐他汀治疗高龄男性ASCVD的疗效及对TGF-β1-Smad2/3通路的影响.[J].中南医学科学杂志.,2023,(2):261-264. |
| 营心宁胶囊联合辛伐他汀治疗高龄男性ASCVD的疗效及对TGF-β1-Smad2/3通路的影响 |
| Therapeutic effect of Yingxinning capsule combined with simvastatin on ASCVD in elderly men and its effect on TGF-β1-Smad2/3 pathway |
| 投稿时间：2022-04-06 修订日期：2022-12-15 |
| DOI：10.15972/j.cnki.43-1509/r.2023.02.026 |
| 中文关键词: ASCVD 营心宁胶囊 TGF-β1-Smad2/3通路 全因死亡 MACE [ |
| 英文关键词:ASCVD Yingxinning capsule TGF-β1-Smad2/3 pathway all cause death MACE |
| 基金项目:武汉市卫健委2020年度科研项目(WZ20C04) |
|
| 摘要点击次数: 132 |
| 全文下载次数: 90 |
| 中文摘要: |
| 目的研究营心宁胶囊治疗高龄男性动脉粥样硬化性心血管疾病(ASCVD)的疗效及对转化生长因子(TGF-β1)-Smad2/3通路的影响。 方法选择高龄男性ASCVD患者,随机分为对照组(辛伐他汀治疗)和联合组(营心宁胶囊联合辛伐他汀治疗)。治疗前及治疗3个月后,分别检测血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDLC)、高密度脂蛋白胆固醇(HDLC)、非HDLC、TGF-β1、Smad2、Smad3的水平,比较两组全因死亡及主要不良心血管事件(MACE)的情况。 结果治疗3个月后,两组TC、LDLC、非HDLC、TGF-β1、Smad2、Smad3均较治疗前降低,且联合组LDLC、非HDLC、TGF-β1、Smad2、Smad3低于对照组(P＜0.05)。联合组全因死亡及MACE发生率低于对照组(P＜0.05)。 结论辛伐他汀联合营心宁胶囊治疗高龄男性ASCVD,可显著降低LDLC并抑制其TGF-β1-Smad2/3通路,显著降低全因死亡及MACE发生率。 |
| 英文摘要: |
| AimTo investigate the therapeutic effect of Yingxinning capsule on atherosclerotic cardiovascular disease (ASCVD) and its effect on transforming growth factor (TGF-β1)-Smad2/3 pathway in elderly men. MethodsElderly male patients with ASCVD were selected and randomly divided into control group (simvastatin) and combination group (Yingxinning capsule combined with simvastatin). Serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), non-HDLC, TGF-β1, Smad2, Smad3 levels were detected before treatment and 3 months after treatment. All-cause death and major adverse cardiovascular events (MACE) were compared between the two groups. ResultsAt 3 months after treatment, TC, LDLC, non-HDLC, TGF-β1, Smad2, Smad3 in both groups were lower than before treatment, and LDLC, non-HDLC, TGF-β1, Smad2, Smad3 in the combined group were lower than those in the control group (P＜0.05). In the combined group, the incidence of all-cause death and MACE was lower than that in the control group (P＜0.05). ConclusionSimvastatin combined with Yingxinning capsule in the treatment of ASCVD in elderly men reduced LDLC significantly, inhibited TGF-β1-Smad2/3 pathway significantly, reduced the incidence of all-cause death and MACE. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|